SCHEMBL6744103

SCHEMBL6744103

N#CCNC(=O)C(CNC(=O)c1ccccc1)S(=O)(=O)Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 8/20 0.53
LMNA P02545 1/20 0.48
RAB9A P51151 1/20 0.48
MAPK14 Q16539 1/20 0.47
CTSS P25774 3/20 0.46
CTSK P43235 3/20 0.46
MLYCD O95822 1/20 0.46
MAPT P10636 1/20 0.46
CTSB P07858 3/20 0.45
GPR139 Q6DWJ6 1/20 0.45
CTSV O60911 1/20 0.45
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
USP2 O75604 2/20 0.44
CYP3A4 P08684 2/20 0.44
NR1I2 O75469 1/20 0.44
ADRB1 P08588 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
ADORA3 P0DMS8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7661637 0.92 CTSL (0.49) CTSLCTSSCTSKCTSBCTSV
SCHEMBL6062636 0.90 CTSL (0.46) CTSLMAPK14CTSSCTSKCTSB
SCHEMBL6744442 0.87 CTSL (0.50) CTSLCTSSCTSKCTSBGPR139
SCHEMBL7662418 0.86 CTSL (0.46) CTSLLMNACTSSCTSKCTSB
SCHEMBL6744437 0.86 CTSL (0.46) CTSLLMNACTSSCTSKCTSB
SCHEMBL6737525 0.86 CTSL (0.46) CTSLCTSSCTSKCTSBGPR139
SCHEMBL6061910 0.86 CTSL (0.56) CTSLCTSSCTSKCTSBCTSV
SCHEMBL6739753 0.85 CTSB (0.62) CTSLRAB9ACTSSCTSKCTSB
SCHEMBL6741513 0.85 CTSL (0.46) CTSLCTSSCTSKMAPTCTSB
SCHEMBL7656391 0.85 CTSL (0.43) CTSLCTSSCTSKCTSBCTSV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors AXYS PHARMACEUTICALS, INC. 2004-01-22 US disclosed
US-6492362-B1 Compounds and compositions as cathepsin S inhibitors AXYS PHARMACEUTICALS, INC. 2002-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors CTSS, CTSB, CTSE CTSL 10/4885LMNA 1476/4885RAB9A 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.